David Gurwitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6875553/publications.pdf

Version: 2024-02-01

239	8,399	46918	54797
papers	citations	47 h-index	84 g-index

247	247	247	11656
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Human Genome Diversity Cell Line Panel. Science, 2002, 296, 261b-262.	6.0	907
2	Angiotensin receptor blockers as tentative SARSâ€CoVâ€2 therapeutics. Drug Development Research, 2020, 81, 537-540.	1.4	636
3	The genome-wide structure of the Jewish people. Nature, 2010, 466, 238-242.	13.7	369
4	Thrombin modulates and reverses neuroblastoma neurite outgrowth.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3440-3444.	3.3	315
5	Refined Geographic Distribution of the Oriental ALDH2*504Lys (nee 487Lys) Variant. Annals of Human Genetics, 2009, 73, 335-345.	0.3	232
6	Reciprocal Modulation of Astrocyte Stellation by Thrombin and Protease Nexin-1. Journal of Neurochemistry, 1990, 54, 1735-1743.	2.1	207
7	Interleukin-6 attenuation of scopolamine-induced amnesia: plausible involvement of cholinergic neuronal survival. NeuroReport, 1997, 8, i-ii.	0.6	148
8	Inhibition of glycogen synthase kinase-3Î² by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochemical and Biophysical Research Communications, 2002, 295, 102-106.	1.0	142
9	The Matrilineal Ancestry of Ashkenazi Jewry: Portrait of a Recent Founder Event. American Journal of Human Genetics, 2006, 78, 487-497.	2.6	140
10	Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8284-8288.	3.3	135
11	Activation of m₁ Muscarinic Acetylcholine Receptor Regulates Ï„ Phosphorylation in Transfected PC12 Cells. Journal of Neurochemistry, 1996, 66, 877-880.	2.1	125
12	Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics, 2006, 7, 783-792.	0.6	124
13	Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. European Journal of Pharmacology, 1994, 267, 21-31.	2.7	121
14	Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Pharmacogenomics Journal, 2005, 5, 221-225.	0.9	119
15	A global view of the OCA2-HERC2 region and pigmentation. Human Genetics, 2012, 131, 683-696.	1.8	113
16	From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 2004, 5, 571-579.	0.6	111
17	Counting the Founders: The Matrilineal Genetic Ancestry of the Jewish Diaspora. PLoS ONE, 2008, 3, e2062.	1.1	101
18	Effects of age and sex on recovery from COVID-19: Analysis of 5769 Israeli patients. Journal of Infection, 2020, 81, e102-e103.	1.7	100

#	Article	IF	Citations
19	The EU-ADR corpus: Annotated drugs, diseases, targets, and their relationships. Journal of Biomedical Informatics, 2012, 45, 879-884.	2.5	99
20	Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends in Pharmacological Sciences, 2003, 24, 122-125.	4.0	96
21	MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population. European Journal of Human Genetics, 2004, 12, 355-364.	1.4	96
22	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics, 2007, 8, 29-39.	0.6	91
23	Muscarinic receptor binding in mouse brain: Regulation by guanine nucleotides. Biochemical and Biophysical Research Communications, 1980, 94, 487-492.	1.0	89
24	SIRT1, miR-132 and miR-212 link human longevity to Alzheimerâ€™s Disease. Scientific Reports, 2018, 8, 8465.	1.6	89
25	Children and Population Biobanks. Science, 2009, 325, 818-819.	6.0	84
26	Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition. Journal of Cellular Physiology, 1990, 142, 155-162.	2.0	83
27	Five novel loci for inherited hearing loss mapped by SNP-based homozygosity profiles in Palestinian families. European Journal of Human Genetics, 2010, 18, 407-413.	1.4	83
28	Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. Journal of Affective Disorders, 2012, 136, 99-103.	2.0	81
29	Single Nucleotide Polymorphism of the Human High Affinity Choline Transporter Alters Transport Rate. Journal of Biological Chemistry, 2002, 277, 45315-45322.	1.6	70
30	Personal genomics services: whose genomes?. European Journal of Human Genetics, 2009, 17, 883-889.	1.4	65
31	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics, 2019, 20, 643-657.	0.6	65
32	M1 Agonists for the Treatment of Alzheimer's Disease.. Annals of the New York Academy of Sciences, 1996, 777, 189-196.	1.8	64
33	The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. European Journal of Human Genetics, 2015, 23, 1116-1123.	1.4	63
34	Agonist-specific reverse regulation of muscarinic receptors by transition metal ions and guanine nucleotides. Biochemical and Biophysical Research Communications, 1980, 96, 1296-1304.	1.0	62
35	(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics, 1991, 257, 392-403.	1.3	61
36	Genome-wide expression profiling of human lymphoblastoid cell lines identifiesCHL1as a putative SSRI antidepressant response biomarker. Pharmacogenomics, 2011, 12, 171-184.	0.6	60

#	Article	IF	Citations
37	Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Translational Psychiatry, 2013, 3, e313-e313.	2.4	60
38	Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study. Molecular Psychiatry, 2021, 26, 1619-1633.	4.1	60
39	Structure-activity studies of the thrombin receptor activating peptide. Biochemical and Biophysical Research Communications, 1992, 188, 604-610.	1.0	59
40	The Distribution and Most Recent Common Ancestor of the 17q21 Inversion in Humans. American Journal of Human Genetics, 2010, 86, 161-171.	2.6	59
41	Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics, 2012, 13, 1129-1139.	0.6	57
42	Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics Journal, 2017, 17, 386-392.	0.9	56
43	Agonist and antagonist binding to rat brain muscarinic receptors: Influence of aging. Neurobiology of Aging, 1987, 8, 115-122.	1.5	55
44	Pharmacogenetics in Europe: Barriers and Opportunities. Public Health Genomics, 2009, 12, 134-141.	0.6	53
45	Proteolytic regulation of neurite outgrowth from neuroblastoma cells by thrombin and protease nexin-1. Journal of Cellular Biochemistry, 1989, 39, 55-64.	1.2	52
46	Dual pathways in muscarinic receptor stimulation of phosphoinositide hydrolysis. Biochemistry, 1987, 26, 633-638.	1.2	49
47	Ancestry inference of 96 population samples using microhaplotypes. International Journal of Legal Medicine, 2018, 132, 703-711.	1.2	48
48	Amyloid Precursor Protein Secretion via Muscarinic Receptors: Reduced Desensitization Using the M1-Selective Agonist AF102B. Biochemical and Biophysical Research Communications, 1994, 203, 652-658.	1.0	47
49	A call for the creation of personalized medicine databases. Nature Reviews Drug Discovery, 2006, 5, 23-26.	21.5	47
50	Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1045-1050.	3.3	45
51	Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. European Journal of Human Genetics, 2009, 17, 991-998.	1.4	43
52	Ethnic differences in alphaâ€1 antitrypsin deficiency allele frequencies may partially explain national differences in COVIDâ€19 fatality rates. FASEB Journal, 2020, 34, 14160-14165.	0.2	43
53	Increased thrombin inhibition in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2005, 79, 351-359.	1.3	42
54	Pharmacogenetics education in British medical schools. Genomic Medicine, 2008, 2, 101-105.	0.6	41

#	Article	IF	Citations
55	Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics, 2010, 11, 327-340.	0.6	40
56	Central muscarinic receptor degeneration following 6-hydroxydopamine lesion in mice. Life Sciences, 1980, 26, 79-84.	2.0	37
57	NGF Promotes Amyloid Precursor Protein Secretion via Muscarinic Receptor Activation. Biochemical and Biophysical Research Communications, 1995, 213, 15-23.	1.0	37
58	Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sciences, 2005, 78, 107-111.	2.0	35
59	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. Journal of Molecular Neuroscience, 2015, 56, 681-687.	1.1	35
60	NGF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating. Journal of Cellular Biochemistry, 1998, 70, 425-432.	1.2	34
61	CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for costâ€“effectiveness studies. Pharmacogenomics, 2009, 10, 685-699.	0.6	34
62	Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics Journal, 2015, 15, 538-548.	0.9	34
63	Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block. Brain, 2008, 131, 1113-1122.	3.7	33
64	High affinity binding of [3H]acetylcholine to muscarinic receptors. Regional distribution and modulation by guanine nucleotides. Molecular Pharmacology, 1985, 28, 297-305.	1.0	33
65	Correlation Between C677T MTHFR Gene Polymorphism, Plasma Homocysteine Levels and the Incidence of CAD. American Journal of Cardiovascular Drugs, 2001, 1, 353-361.	1.0	32
66	Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. European Neuropsychopharmacology, 2004, 14, 237-243.	0.3	32
67	Personalized medicine: decades away?. Pharmacogenomics, 2006, 7, 237-241.	0.6	31
68	â€˜Drug reactions, enzymes, and biochemical geneticsâ€™: 50 years later. Pharmacogenomics, 2007, 8, 1479-1484.	0.6	31
69	Smoking and <scp>COVID</scp>â€19: Similar bronchial <scp>ACE2</scp> and <scp>TMPRSS2</scp> expression and higher <scp>TMPRSS4</scp> expression in current versus never smokers. Drug Development Research, 2020, 81, 1073-1080.	1.4	31
70			

#	Article	IF	Citations
73	Health technology assessment in the era of personalized health care. International Journal of Technology Assessment in Health Care, 2011, 27, 118-126.	0.2	28
74	Selective Signaling via Unique Ml Muscarinic Agonistsa. Annals of the New York Academy of Sciences, 1993, 695, 300-303.	1.8	27
75	Induced interconversion of agonist affinity states in muscarinic receptor from mice brain: Effects of temperature and sugars. Biochemical and Biophysical Research Communications, 1980, 94, 493-500.	1.0	26
76	Quantitative measurements of mouse brain thrombin-like and thrombin inhibition activities. NeuroReport, 2001, 12, 2347-2351.	0.6	26
77	Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology, 2005, 210, 781-788.	0.8	26
78	Identification of signaling pathways associated with cancer protection in Laron syndrome. Endocrine-Related Cancer, 2016, 23, 399-410.	1.6	26
79	Polymorphisms of CYP2C19 and CYP2D6 in Israeli Ethnic Groups. Molecular Diagnosis and Therapy, 2004, 4, 395-401.	3.3	25
80	Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. Molecular Psychiatry, 2021, 26, 6550-6561.	4.1	25
81	Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders. Dialogues in Clinical Neuroscience, 2016, 18, 267-276.	1.8	25
82	TPMT testing in azathioprine: a â€˜cost-effective use of healthcare resourcesâ€™?. Personalized Medicine, 2009, 6, 103-113.	0.8	23
83	RGS2 expression predicts amyloid-Î² sensitivity, MCI and Alzheimerâ€™s disease: genome-wide transcriptomic profiling and bioinformatics data mining. Translational Psychiatry, 2016, 6, e909-e909.	2.4	23
84	Copper ions and diamide induce a high affinity guanine-nucleotide-insensitive state for muscarinic agonists. Biochemical and Biophysical Research Communications, 1984, 120, 271-277.	1.0	22
85	Recognition of the muscarinic receptor by its endogenous neurotransmitter: binding of [3H]acetylcholine and its modulation by transition metal ions and guanine nucleotides.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 3650-3654.	3.3	22
86	Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. Pharmacogenomics, 2013, 14, 337-339.	0.6	22
87	CHL1,ITGB3andSLC6A4gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics, 2015, 16, 689-701.	0.6	22
88	Estradiol reduces <scp>ACE2</scp> and <scp>TMPRSS2 mRNA</scp> levels in <scp>A549</scp> human lung epithelial cells. Drug Development Research, 2022, 83, 961-966.	1.4	22
89	Altered Ontogenesis of Muscarinic Receptors in Agranular Cerebellar Cortex. Journal of Neurochemistry, 1982, 39, 756-763.	2.1	21
90	Expression of muscarinic binding sites in primary human brain tumors. Developmental Brain Research, 1984, 14, 61-70.	2.1	21

#	Article	IF	Citations
91	Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics, 2009, 10, 157-159.	0.6	21
92	A gene co-expression module implicating the mitochondrial electron transport chain is associated with long-term response to lithium treatment in bipolar affective disorder. Translational Psychiatry, 2018, 8, 183.	2.4	21
93	Increased agonist affinity is induced in tetranitromethane-modified muscarinic receptors. Biochemistry, 1985, 24, 8086-8093.	1.2	20
94	Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. Life Sciences, 1996, 59, 1651-1657.	2.0	20
95	Personalized psychiatry: a realistic goal. Pharmacogenomics, 2004, 5, 213-217.	0.6	20
96	Grant Application Review: The Case of Transparency. PLoS Biology, 2014, 12, e1002010.	2.6	20
97	MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action. Frontiers in Molecular Neuroscience, 2017, 10, 355.	1.4	20
98	COVID-19 vaccine hesitancy: Lessons from Israel. Vaccine, 2021, 39, 3785-3786.	1.7	20
99	NGF-dependent neurotrophic-like effects of AF102B, anM1 Muscarinic agonist, in PC12M1 cells. NeuroReport, 1995, 6, 485-488.	0.6	19
100	Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics, 2007, 8, 713-719.	0.6	19
101	Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines. Genome Medicine, 2015, 7, 37.	3.6	19
102	Ligand-selective signaling and high-content screening for GPCR drugs. Drug Discovery Today, 2003, 8, 1108-1109.	3.2	18
103	Pharmacogenomic Testing: Knowing More, Doing Better. Clinical Pharmacology and Therapeutics, 2012, 91, 387-389.	2.3	18
104	Gene drives raise dual-use concerns. Science, 2014, 345, 1010-1010.	6.0	17
105	Repurposing current therapeutics for treating COVID â€19: A vital role of prescription records data mining. Drug Development Research, 2020, 81, 777-781.	1.4	17
106	Pharmacogenetics education: 10 years of experience at Tel Aviv University. Pharmacogenomics, 2010, 11, 647-649.	0.6	16
107	Dehydroepiandrosterone Augments M1â€Muscarinic Receptorâ€Stimulated Amyloid Precursor Protein Secretion in Desensitized PC12M1 Cells. Annals of the New York Academy of Sciences, 1995, 774, 300-303.	1.8	15
108	Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. Pharmacogenomics, 2012, 13, 543-554.	0.6	15

#	Article	IF	Citations
109	Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy. Translational Psychiatry, 2016, 6, e950-e950.	2.4	15
110	Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?. Dialogues in Clinical Neuroscience, 2018, 20, 293-300.	1.8	15
111	Do endogenous cannabinoids contribute to HIV-mediated immune failure?. Trends in Molecular Medicine, 1998, 4, 196-200.	2.6	14
112	Exosomal MicroRNAs in Tissue Crosstalk. Drug Development Research, 2015, 76, 259-262.	1.4	14
113	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. Clinical Pharmacology and Therapeutics, 2019, 106, 313-316.	2.3	14
114	Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics, 2007, 8, 311-314.	0.6	13
115	Sex Differences in Human Lymphoblastoid Cells Sensitivities to Antipsychotic Drugs. Journal of Molecular Neuroscience, 2013, 49, 554-558.	1.1	13
116	Expression profiling: a cost-effective biomarker discovery tool for the personal genome era. Genome Medicine, 2013, 5, 41.	3.6	13
117	Characterization of human lymphoblastoid cell lines as a novel in vitro test system to predict the immunotoxicity of xenobiotics. Toxicology Letters, 2015, 233, 8-15.	0.4	13
118	Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. Translational Psychiatry, 2016, 6, e827-e827.	2.4	13
119	Peripheral Blood Mononuclear Cell Oxytocin and Vasopressin Receptor Expression Positively Correlates with Social and Behavioral Function in Children with Autism. Scientific Reports, 2019, 9, 13443.	1.6	13
120	RNA sequencing of bipolar disorder lymphoblastoid cell lines implicates the neurotrophic factor HRP-3 in lithiumâ€™s clinical efficacy. World Journal of Biological Psychiatry, 2019, 20, 449-461.	1.3	13
121	Flight attendants, breast cancer, and melatonin. Lancet, The, 1998, 352, 1388-1390.	6.3	12
122	Elevated Cerebrospinal Fluid Glutamate in Patients With HIV-related Dementia. JAMA - Journal of the American Medical Association, 1997, 277, 1931.	3.8	11
123	The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns. Drug Discovery Today, 2002, 7, 403-406.	3.2	11
124	Biochemical Characterization of the Muscarinic Receptors. Advances in Enzymology and Related Areas of Molecular Biology, 2006, 55, 137-196.	1.3	11
125	Increased KPI containing amyloid precursor protein in experimental autoimmune encephalomyelitis brains. NeuroReport, 2007, 18, 581-584.	0.6	11
126	Rat brain and heart muscarinic receptors: Modification with tetranitromethane. Biochemical and Biophysical Research Communications, 1985, 131, 1124-1131.	1.0	10

#	Article	IF	Citations
127	Rigid analogs of acetylcholine can be m1-selective agonists: implications for a rational treatment strategy in Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 839-844.	1.0	10
128	Novel 5-HT1A-receptor agonists: F11440, MKC242 and BAYx3702. Drug Discovery Today, 1999, 4, 142-143.	3.2	10
129	Animal models and human genome diversity: the pitfalls of inbred mice. Drug Discovery Today, 2001, 6, 766-768.	3.2	10
130	Progress in medicinal chemistry of novel selective muscarinic agonists. Drug Design and Discovery, 1993, 9, 221-35.	0.3	10
131	Protease nexin-1 complexes and inhibits T cell serine proteinase-1. Biochemical and Biophysical Research Communications, 1989, 161, 300-304.	1.0	9
132	Peroxynitrite generation might explain elevated glutamate and aspartate levels in multiple sclerosis cerebrospinal fluid. European Journal of Clinical Investigation, 1998, 28, 760-761.	1.7	9
133	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics, 2007, 8, 519-519.	0.6	9
134	Cataloging the interactome of small molecules and the human proteome. Drug Development Research, 2011, 72, 1-3.	1.4	9
135	Genome-wide transcriptomic variations of human lymphoblastoid cell lines: insights from pairwise gene-expression correlations. Pharmacogenomics, 2012, 13, 1893-1904.	0.6	9
136	Recent Selection on a Class I ADH Locus Distinguishes Southwest Asian Populations Including Ashkenazi Jews. Genes, 2018, 9, 452.	1.0	9
137	Are drug targets missed owing to lack of physical activity?. Drug Discovery Today, 2001, 6, 342-343.	3.2	8
138	Personalized Pharmacotherapy: Genotypes, Biomarkers, and Beyond. Clinical Pharmacology and Therapeutics, 2009, 85, 142-142.	2.3	8
139	N-methyl-citalopram: A quaternary selective serotonin reuptake inhibitor. Biochemical Pharmacology, 2010, 80, 1546-1552.	2.0	8
140	The Gut Microbiome: Insights for Personalized Medicine. Drug Development Research, 2013, 74, 341-343.	1.4	8
141	Genomics and the future of psychopharmacology: MicroRNAs offer novel therapeutics. Dialogues in Clinical Neuroscience, 2019, 21, 131-148.	1.8	8
142	Targeting Alzheimer's disease: Is there a light at the end of the tunnel?. Drug Development Research, 2002, 56, 45-48.	1.4	7
143	Ethnic differences of coronary artery disease-associated SNPs in two Israeli healthy populations using MALDI-TOF mass spectrometry. Life Sciences, 2004, 75, 1003-1010.	2.0	7
144	â€˜Private fears in public places?â€™ Ethical and regulatory concerns regarding human genomic databases. Personalized Medicine, 2007, 4, 447-452.	0.8	7

#	Article	IF	Citations
145	Editorial (Forward Look: Tenth Anniversary of the Human Genome Sequence and 21st Century) Tj ETQq1 1 0.784314 rgBT /Overlock 10 and Personalized Medicine, 2011, 9, 148-155.	0.2	7
146	Farm Microbiome and Childhood Asthma. New England Journal of Medicine, 2011, 364, 1972-1973.	13.9	7
147	Genetic relationships of Southwest Asian and Mediterranean populations. Forensic Science International: Genetics, 2021, 53, 102528.	1.6	7
148	Auguste D and Alzheimer's disease. Lancet, The, 1997, 350, 298.	6.3	6
149	Oestrogen replacement therapy in postmenopausal women. Lancet, The, 1999, 353, 674-675.	6.3	6
150	Head circumference and incident Alzheimerâ€™s disease: Modification by apolipoprotein E. Neurology, 2002, 58, 1440-1440.	1.5	6
151	Genetic privacy: Trust is not enough. Science, 2015, 347, 957-958.	6.0	6
152	Emerging therapeutic targets. Drug Discovery Today, 1998, 3, 426.	3.2	5
153	Applying pharmacogenomics in drug development: Call for collaborative efforts. Drug Development Research, 2004, 62, 71-75.	1.4	5
154	Personalized participatory medicine: sharing knowledge and uncertainty. Genome Medicine, 2011, 3, 69.	3.6	5
155	SCN11A mRNA levels in female bipolar disorder PBMCs as tentative biomarker for distinct patient subâ€phenotypes. Drug Development Research, 2019, 80, 1128-1135.	1.4	5
156	Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. Psychoneuroendocrinology, 2021, 129, 105234.	1.3	5
157	Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy. Journal of Psychiatric Research, 2021, 141, 92-103.	1.5	5
158	Ancestry in translational genomic medicine: handle with care. Genome Medicine, 2009, 1, 24.	3.6	4
159	From Transcriptomics to Biological Networks. Drug Development Research, 2014, 75, 267-270.	1.4	4
160	Peptide Mimetics: Fastâ€Forward Look. Drug Development Research, 2017, 78, 231-235.	1.4	4
161	Selective Signaling Via Novel Muscarinic Agonists: Implications for Alzheimerâ€™s Disease Treatments and Clinical Update. , 1994, , 219-223.		4
162	Selective neurotoxicity induced by the ionophore lasalocid in rat dissociated cerebral cultures, involvement of the NMDA receptor/channel. NeuroToxicology, 1996, 17, 883-95.	1.4	4

#	Article	IF	Citations
163	Selective neurotoxicity induced by lasalocid in dissociated cerebral cultures. Toxicology in Vitro, 1993, 7, 345-352.	1.1	3
164	Abnormal potassium-channel function in platelets in Alzheimer's disease. Lancet, The, 1999, 353, 326.	6.3	3
165	Personalized medicine in psychiatry. Personalized Medicine, 2004, 1, 15-18.	0.8	3
166	Malaria drugs: clues from malaria resistance genetics. Drug Development Research, 2010, 71, 1-3.	1.4	3
167	The Alzheimer's disease peptide Î²-amyloid promotes thrombin generation through activation of coagulation factor XII: comment. Journal of Thrombosis and Haemostasis, 2016, 14, 1488-1489.	1.9	3
168	RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimerâ€™s Disease. , 2017, , 239-251.		3
169	Nuclear Î±vÎ²3 integrin expression, post translational modifications and regulation in hematological malignancies. Hematological Oncology, 2022, 40, 73-82.	0.8	3
170	New M1 Agonists: Selective Signaling, Neurotrophic-Like and Cognitive Effects â€" Implications in the Treatment of Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1995, , 449-455.	0.2	3
171	Physical activity: good for your health, very good for your gene expression. Clinical Genetics, 2000, 57, 249-251.	1.0	3
172	Complex traits, complex answers. Molecular Psychiatry, 1997, 2, 89-90.	4.1	2
173	New imaging techniques for early diagnosis of Alzheimerâ€™s disease. Trends in Neurosciences, 2000, 23, 386.	4.2	2
174	Fatty acid amide hydrolase inhibitors and the marijuana debate. Lancet, The, 2001, 358, 1548.	6.3	2
175	Profile. Drug Discovery Today, 2001, 6, 1178-1179.	3.2	2
176	Inducing apoptosis: mind the natural killer cellsâ–¾. Drug Discovery Today, 2003, 8, 292.	3.2	2
177	Pharmacogenomics of schizophrenia: Towards personalized psychiatry. Drug Development Research, 2003, 60, 71-74.	1.4	2
178	New drug targets for depression and anxiety: Is the peptides era arriving?. Drug Development Research, 2005, 65, 93-96.	1.4	2
179	Serotonin uptake to lymphocytes of patients with social phobia compared to normal individuals. European Neuropsychopharmacology, 2006, 16, 19-23.	0.3	2
180	Responseâ€"Biobanks. Science, 2009, 326, 799-799.	6.0	2

#	Article	IF	Citations
181	Guarding children's genetic privacy. Nature, 2013, 494, 430-430.	13.7	2
182	MicroRNAs as CNS Drug Targets. Drug Development Research, 2016, 77, 331-335.	1.4	2
183	Award bonus points to motivate reviewers. Nature, 2017, 542, 414-414.	13.7	2
184	Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries. Vaccine, 2021, 39, 1027.	1.7	2
185	Genome wide analysis implicates upregulation of proteasome pathway in major depressive disorder. Translational Psychiatry, 2021, 11, 409.	2.4	2
186	d â€Galactose treatment increases ACE2 , TMPRSS2 , and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cells. Drug Development Research, 2021, , .	1.4	2
187	Neurotoxicity of apolipoprotein E thrombin cleavage fragments: implications for Alzheimer's disease. NeuroReport, 1997, 8, 1067-8.	0.6	2
188	Higher ATM expression in lymphoblastoid cell lines from centenarian compared with younger women. Drug Development Research, 0, , .	1.4	2
189	Chorionic villus sampling versus early amniocentesis. Lancet, The, 1997, 350, 1254.	6.3	1
190	Haemorrhagic shock: endogenous cannabinoids to the rescue. Trends in Molecular Medicine, 1998, 4, 99.	2.6	1
191	Complement depletion or blockade could save lives of sepsis victims. Trends in Molecular Medicine, 1999, 5, 376.	2.6	1
192	AMPA receptors: a better target for ischaemic brain damage?. Trends in Molecular Medicine, 1999, 5, 464.	2.6	1
193	Molecular cancer target: PI-3-kinase. Drug Discovery Today, 1999, 4, 96.	3.2	1
194	The therapeutic potential of nicotine and nicotinic agonists for weight control. Expert Opinion on Investigational Drugs, 1999, 8, 747-760.	1.9	1
195	Should Third-World countries pay the tab for new drug development?. Academic Medicine, 1999, 74, 203.	0.8	1
196	Receptor crosstalk: a surprising twist on an old concept. Trends in Molecular Medicine, 2000, 6, 261.	2.6	1
197	A primer for personalized medicine. Trends in Molecular Medicine, 2002, 8, 408.	3.5	1
198	Workshop Abstracts. Personalized Medicine, 2005, 2, 145-185.	0.8	1

#	Article	IF	Citations
199	Response to Sykiotis and Papavassiliou: Professional education in molecular medicine â€“ pharmacogenetics first. Trends in Molecular Medicine, 2005, 11, 485-486.	3.5	1
200	Metabolic syndrome: a wake-up call. Drug Development Research, 2006, 67, 535-538.	1.4	1
201	Prioritizing migraine biomarkers research. Drug Development Research, 2007, 68, 267-269.	1.4	1
202	Informing resource allocation decision making: economic evaluations of pharmacogenetic tests. Drug Development Research, 2010, 71, 445-448.	1.4	1
203	A deserving role for the National Center for Advancing Translational Sciences. Lancet, The, 2011, 377, 1745-1746.	6.3	1
204	Biomarkers: better donor protection. Nature, 2011, 470, 175-175.	13.7	1
205	Data Re-Identification: Protect the Children. Science, 2013, 339, 1033-1033.	6.0	1
206	Conference Scene: Pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics, 2014, 15, 739-744.	0.6	1
207	Affective disorders: susceptibility and drug efficacy may be determined by the serotonin transporter promoter polymorphism. Clinical Genetics, 2000, 57, 247-249.	1.0	1
208	Human lymphoblastoid cell lines: a valuable tool for personalized medicine research. Biochemist, 2016, 38, 6-9.	0.2	1
209	Telomerase expression and cancer: a controversy finally put to rest?. Clinical Genetics, 1999, 55, 306-8.	1.0	1
210	Beneficial effects of statins. Lancet, The, 1996, 348, 1583.	6.3	0
211	Uric acid might herald new hopes for multiple sclerosis patients. Trends in Molecular Medicine, 1998, 4, 144.	2.6	0
212	New evidence for neuroprotection by estrogen. Trends in Molecular Medicine, 1998, 4, 281.	2.6	0
213	Emerging molecular targets. Drug Discovery Today, 1998, 3, 144.	3.2	0
214	Emerging molecular targets. Drug Discovery Today, 1998, 3, 388-389.	3.2	0
215	Sperm conceive cues in surprising ways. Trends in Molecular Medicine, 1999, 5, 8.	2.6	0
216	Coronary artery disease therapy: as as simple as l-arginine?. Trends in Molecular Medicine, 1999, 5, 98.	2.6	0

#	Article	IF	Citations
217	Marihuana and medicine: the debate persists. Trends in Molecular Medicine, 1999, 5, 378.	2.6	0
218	Pharmacogenetic-oriented drug development. Drug Discovery Today, 1999, 4, 151-152.	3.2	0
219	Correspondence. American Journal of Medicine, 1999, 107, 189-190.	0.6	0
220	Israel's biotech: The next conquest. Drug Development Research, 2000, 50, 203-206.	1.4	0
221	Renewed hope for medicinal marijuana?. Trends in Molecular Medicine, 2000, 6, 187.	2.6	0
222	New hope for spinal-cord repair from immune activation. Trends in Molecular Medicine, 2000, 6, 415.	2.6	0
223	Cancer therapy: A2B adenosine antagonists for busting tumor angiogenesis?. Trends in Molecular Medicine, 2000, 6, 6.	2.6	0
224	Mast-cell chymase: a new target for anti-inflammatory drugs. Trends in Molecular Medicine, 2000, 6, 99.	2.6	0
225	Seasonality of birth in patients with type 1 diabetes. Lancet, The, 2002, 359, 1247.	6.3	0
226	Workshop Introduction: Personalized medicine: desirable, affordable, attainable?. Personalized Medicine, 2005, 2, 143-144.	0.8	0
227	Personalized Medicine. , 2007, , 279-295.		0
228	Cancer therapeutics: reflections on natural killer cells. Drug Development Research, 2008, 69, 285-288.	1.4	0
229	Biomarkers: improving the costâ€effectiveness of biological drugs for autoimmune disorders. Drug Development Research, 2011, 72, 549-552.	1.4	0
230	Highâ€Quality Phenomics are Crucial for Informative Omics Studies. Drug Development Research, 2012, 73, 353-356.	1.4	0
231	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. European Neuropsychopharmacology, 2013, 23, S168-S169.	0.3	0
232	A Biological Basis for the Sex Bias of Antipsychotic Drugs Adverse Events. Journal of the American Geriatrics Society, 2013, 61, 1437-1437.	1.3	0
233	Personalizing Anticoagulant and Antiplatelet Therapeutics: A Timely Task. Drug Development Research, 2013, 74, 403-405.	1.4	0
234	Keep files small to curb energy use. Nature, 2014, 514, 305-305.	13.7	0

#	Article	IF	Citations
235	Wholeâ€genome sequencing for combatting antibiotic resistance. Drug Development Research, 2019, 80, 3-5.	1.4	0
236	Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine â€“ A Welcome to Editors-In-Chief Adrian LLerena (Spain) and Ross A. McKinnon (Australia). Current Pharmacogenomics and Personalized Medicine, 2013, 11, 87-92.	0.2	0
237	Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimerâ€™s Disease. , 1997, , 317-322.		0
238	p53 gene polymorphism and cancer risk: the debate continues. Clinical Genetics, 1999, 55, 305-6.	1.0	0
239	P.0061 Ketamine affects expression of Itgb3, Itgav, Chl1 and Sirt1 in the prefrontal cortex of rats in a depressive-like behaviour model. European Neuropsychopharmacology, 2021, 53, S44-S45.	0.3	0